Skip to main content
. 2022 Feb;14(2):396–404. doi: 10.21037/jtd-22-26

Figure 2.

Figure 2

Changes in the cardiometabolic risk biomarkers at 0, 3, 6, 9, 12, and 15 weeks of follow-up in T2DM patients with CHD. T2DM, type 2 diabetic metabolism; HOMA-IR, homeostatic model assessment for insulin resistance; FPG, fasting plasma glucose; BMI, body mass index; hs‐CRP, high‐sensitivity C‐reactive protein.